Adverse effects of chronic low level lead exposure on kidney function - A risk group study in children

Nephrology Dialysis Transplantation

Volumn 13, Issue 9, 1998, Pages 2248-2256

  Fels, Lüder M ^a   Wünsch, Markus ^a   Baranowski, Jacek ^b   Norska Borówka, Irena ^b   Price, Robert G ^c   Taylor, Sarah A ^c   Patel, Sharmila ^c   De Broe, Marc ^d   Elsevier, Monique M ^d   Lauwerys, Robert ^e   Roels, Harry ^e   Bernard, Alfred ^e   Mutti, Antonio ^f   Gelpí, Emilio ^g   Roselló, Joan ^g   Stolte, Hilmar ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f UNIVERSITY OF PARMA   (Italy)

^g CSIC   (Spain)

Author keywords

Children; Clara cell protein; EGF; Eicosanoids; Glomerular and tubular function; Lead exposure

Indexed keywords

BETA 2 MICROGLOBULIN; CELL PROTEIN; EPIDERMAL GROWTH FACTOR; ICOSANOID; KIDNEY ENZYME; LEAD; PLASMA PROTEIN; PROSTAGLANDIN; THROMBOXANE B2;

ARTICLE; CLARA CELL; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; KIDNEY DISTAL TUBULE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHRON; PRIORITY JOURNAL; SCHOOL CHILD; URINARY EXCRETION;

BIOLOGICAL MARKERS; BLOOD; CHILD; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; KIDNEY; KIDNEY TUBULES, DISTAL; KIDNEY TUBULES, PROXIMAL; LEAD; MALE; RISK FACTORS; TIME FACTORS; URINE;

EID: 7344268572     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.9.2248     Document Type: Article

References (48)

1. EPA (Environmental Protection Agency). Evaluation of the potential carcinogenicity of lead and lead compounds. EPA-600/8 89/045A. 1989: US EPA, Washington, DC
2. Houk VN. Implications of newer data for screening and evaluation of children. In: Needleman HL, ed. Low Level Lead Exposure: The Clinical Implications of Current Research. Raven Press, New York: 1980: 231-237
3. Cardenas A, Roels H, Bernard AM et al. Markers of renal changes induced by industrial pollutants. II. Applications to workers exposed to lead. Br Med J 1993; 50: 17-27
4. Pergande M, Jung K, Precht S, Fels LM, Herbort C, Stolte H. Changed excretion of urinary proteins and enzymes by chronic exposure to lead. Nephrol Dial Transplant 1994; 9: 613-618
5. Fels LM, Herbort C. Pergrande M et al. Nephron target sites in chronic exposure to lead. Nephrol Dial Transplant 1994; 9: 1740-1746
6. Krause C, Babisch W, Becker K et al. Umwelt-Survey 1990/92. Band Ia: Studienbeschreibung und Human-Biomonitoring-Deskription der Spurenelementgehalte in Blut und Urin der Bevölkerung in der Bundesrepublik Deutschland. Institut für Wasser-, Boden- und Lufthygiene des Umweltbundesamtes (Institute for Water, Soil and Air of the Federal Environmental Agency, Berlin, Germany), WaBoLu-Heft 1, 1996
7. Mushak P. Davis JM, Crocetti AF, Grant LD. Review. Prenatal and postnatal effects of low-level lead exposure: integrated summary of a report to the U.S. Congress on childhood lead poisoning. Environ Res 1989; 50:11-36
8. Winneke G, Brockhaus A, Ewers U, Krämer U, Neuf M. Results from the European multi-center study on lead neurotoxicity in children: implications for risk assessment. Neurotoxicol Teratol 1990; 12: 553-559
9. Centers for Disease Control and Prevention. Preventing Lead Poisoning in Young Children. US Department of Health and Human Services, Atlanta, GA: 1991
10. Goyer RA. Toxic effects of metals. In: Amdur MO, Doull J, Kaassen CD, eds Toxicology, 4th edn. Pergamon Press, New York: 1993: 623-680
11. Schwartz J, Landrigan PJ, Baker EL, Orenstein WA, Von Lindern IH. Lead-induced anemia: dose response relationships and evidence for a threshold. Am J Public Health 1990; 80: 165-168
12. Bernard AM, Vyskocil A, Roels H, Kriz J, Kodl M, Lauwerys R. Renal effects in children living in the vicinity of a lead smelter. Environ Res 1995; 68: 91-95
13. Kommission 'Human-Biomonitoring' des Umweltbundesamtes. Stoffmonographie Blei-Referenz- und Biomonitoring-Werte (HBM). Bundesgesundhbl 1996; 6: 236-241
14. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
15. Laemmli UK. Cleavage of structural proteins in the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
16. Bernard A, Lauwerys R. Continuous flow system for automation of latex immunoassay by particle counting. Clin Chem 1983; 29: 1007-1011
17. Mutti A, Lucertini S, Valcavi P et al. Urinary excretion of brush-border antigen revealed by monoclonal antibody: early indicator of toxic nephropathy. Lancet 1985; 2: 914-917
18. Verpooten GF, Nuyts GD, Hoylarts MF et al. Immunoassay in urine of a specific marker for proximal tubular S3 segment Clin Chem 1992; 38: 642-647
19. Nouwen EJ, Verstrepen WA, De Broe ME. Epidermal growth factor in acute renal failure. Renal Failure 1994; 16: 49-60
20. Engval E: Fibronectin. In: Bergmeyer HV, ed. Methods of Enzymatic Analysis. Verlag Chemie, Weinheim, Germany: 1986: 201
21. Price RG, Taylor SA, Crutcher E, Bergamaschi E, Franchini I, Mackie AD. The assay of laminin fragments in serum and urine as an indicator of renal damage induced by toxins. Toxicol Lett 1995; 77: 313-318
22. Gelpi E, Ramis I, Hotter G, Bioque G, Bulbena O, Roselló J. Modern high-performance liquid chromatographic radioimmunoassay strategies for the study of eicosanoids. J Chromatogr 1989; 492: 223-250
23. Kristz W, Samaan GJ, Leberre C, Demelier JF, Biou D. Semi automated fluorometric assay for urinary total and B N-acetyl-beta-D-glucosaminidase: analytical investigation. J Clin Lab 1991; 5: 1-2
24. Tucker SM, Boyd PJR, Thompson AE, Price RG. Automated assay of N-acetyl-β-D-glucosaminidase in normal and pathological human urine. Clin Chim Acta 1975; 62: 333-339
25. Mattenheimer H, Frölke W, Grötsch H, Maruhn D, Simane Z. Recommendation for the measurement of 'alanine aminopeptidase' in urine. J Clin Chem Clin Biochem 1988; 26: 635-644
26. Wahlefeld AW, Bermeyer HU. γ-Glutamyltransferase. Routine method. In: Bermeyer HU, Bergmeyer J, Grassi M, eds Methods of Enzymatic Analysis. Verlag Chemie, Weinheim, Germany: 1994; Vol. 3: 352-356
27. Merck, Klinisches Laboratorium, 12th edition E. Merck, Darmstadt, Germany: 1974: 473-478
28. 2-Microglobulin instability in pathological urine. Clin Chem 1982; 28: 1330-1333
29. Bernard A, Lauwerys R. Low-molecular weight proteins as markers of organ toxicity with special reference to Clara cell protein. Toxicol Lett 1995; 77: 145-151
30. Roels H, Lauwerys R. Evaluation of dose effect and dose-response relationships for lead exposure in different Belgian population groups (fetus, child, adult men and women). Trace Elements Med 1987; 4: 80-87
31. Bonvalet JP, Pradelles P, Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 1987; 253: F377-F387
32. Klahr S. Role of arachidonic acid metabolites in acute renal failure and sepsis. Nephrol Dial Transplant 1994; 9 [Suppl 4]: 52-56
33. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1-12
34. Remuzzi G, Fitzgerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992; 41: 1483-1493
35. Stoff JS. Prostaglandins and hypertension. Am J Med 1986; 80 [Suppl 1A]: 56-61
36. Victery W. Evidence for effects of chronic lead exposure on blood pressure in experimental animals: an overview. Environ Health Perspect 1988; 78: 71-76
37. Verberk MM, Willems TE, Verplanke AJ, De Wolff FA. Environmental lead and renal effects in children. Arch Environ Health 1996; 51: 83-87
38. Simane ZJ. Lysosomal enzymes. In: Jung K, Mattenheimer H, Buchardt U, eds Urinary Enzymes in Clinical and Experimental Medicine. Springer Verlag, Berlin/Heidelberg: 1992: 118-124
39. Bernard A, Thielemans N, Roels H, Lauwerys R. Association between NAG B and cadmium in urine with no evidence of a threshold. Occup Environ Med 1995; 52: 177-180
40. Ginevri F, Mutti A, De Toni T, Ghiggeri GM, Perfumo F, Gusmano R. Normal levels of urinary brush-border antigens and other tubular markers in children. Pediatr Nephrol 1993; 7: 240-241
41. Khalil-Manesh F, Gonick HC, Cohen AH et al. Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney Int 1992; 41: 1192-1203
42. Verstrepen WA, Nouwen EJ, De Broe ME. Renal epidermal growth factor and insulin-like growth factor I in acute renal failure. Nephrol Dial Transplant 1994; 9 [Suppl 5]: 57-68
43. Kim DC, Hanano M, Kanai Y, Ohnuma N, Sugiyama Y. Localization of binding sites for epidermal growth factor (EGF) in rat kidney: evidence for the existence of low affinity EGF binding sites on the brush border membrane. Pharmacol Res 1992; 9: 1394-1401
44. Burns KD, Capdevila J, Wei S, Breyer MD, Homma T, Harris RC. Role of cytochrome P-450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Am J Physiol 1995; 269: C831-C840
45. Taira T, Yoshimura A, Iizuka K, Iwasaki S, Ideura T, Koshikawa S. Urinary epidermal growth factor levels in patients with acute renal failure. Am J Kidney Dis 1993; 22: 656-661
46. Jorgensen PE, Kamper AL, Munck O, Strandgaard S, Nexo E. Urinary excretion of epidermal growth factor in living human kidney donors and their recipients. Eur J Clin Invest 1995; 25: 442-446
47. Sundberg AGM, Nilsson R, Appelkvist E, Dallner G. Immunohistochemical localisation of alpha and pi class glutathione transferases in normal human tissues. Pharmacol Toxicol 1993; 72: 321-331
48. Sundberg AGM, Appelkvist E, Backman L, Dallner G. Urinary π-class glutathione transferase as an indicator of tubular damage in the human kidney. Nephron 1994; 67: 308-316